I don't think we'll see notable price separation between these stocks until Q1 sales are reported, or NCE status. The high speed trading programs have pulled these into the same trading rhythm. It's possible that AMRN and ARNA are equally represented in a popular biotech ETF. this would explain why they trade the same no matter what. The only way to get separation is for the EtF to program the separation based on sales or what they deem a significant event.
If I had to guess I'd go with ARNa reaching $9 first, followed by AMRN hitting $9 ten seconds later. :)
to expand, Until recently I had planned adding to one of my otehr bio's, like ARNA or NVIV. But when you look at how AMRN got beat down to the 8's, and you look at the fact the sNDA for Anchor will be submitted at anytime now, and the fact that FDA approval will expand potential sales from 1bil to 10bil, and also a possible NCE approval next week (this would just be a bonus, it's already priced out imo), then right now imo is an absolute steal getting AMRN at this price. I believe sales will be fantastic as they have the same team taht launched lovaza and they now have the best product going in Vascepa. Just a no lose buy with AMRN imo. I think ARNA will do great, but it's all sales based now and will take some time. AMRN will move now imo, glta and do your own dd.